<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879007</url>
  </required_header>
  <id_info>
    <org_study_id>LG-AACL006</org_study_id>
    <nct_id>NCT01879007</nct_id>
  </id_info>
  <brief_title>Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)</brief_title>
  <official_title>Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous&#xD;
      Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation (Gemifloxacin&#xD;
      320mg) and to explore possibility of clinical use of the IV formulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>F</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received one intravenous administration and one oral medication with interval of 1 week,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received one oral administration and one intravenous medication with interval of 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FactiveÂ® Tab / Factive IV</intervention_name>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Korean males between 19 and 45 years of age, weighing within 15% deviation of&#xD;
             the ideal weight (CRC criteria) and residing in Korea (Appendix 4)&#xD;
&#xD;
          2. Applicants judged eligible as subject based on health exams (interview, blood&#xD;
             pressure, 12-lead ECG, physical exam, blood and urine tests, and other screening&#xD;
             tests) conducted not more than three weeks prior to administration (those with two or&#xD;
             less clinically significant results)&#xD;
&#xD;
          3. Applicants who can take part in the whole process of clinical study&#xD;
&#xD;
          4. Applicants who sufficiently received explanation on the purpose and content of&#xD;
             clinical study, characteristics of the investigational products, etc., before&#xD;
             participating in the study and gave written consent to participate in the study&#xD;
             voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Applicants who exhibit symptoms suspected to be those of acute diseases prior to the&#xD;
             start of the study&#xD;
&#xD;
          2. Clinically significant kidney disease or liver disease&#xD;
&#xD;
          3. Cardiovascular, respiratory, renal, endocrine system, hematology (hemorrhagic&#xD;
             diathresis), digestive system (peptic ulcer), central nerve system, psychiatric&#xD;
             disorder, or malignant tumors; chronic diseases that can influence the absorption,&#xD;
             distribution, metabolism, or excretion of drugs&#xD;
&#xD;
          4. Applicants who have been on an abnormal diet, which can influence the absorption,&#xD;
             distribution, metabolism, or excretion of drugs&#xD;
&#xD;
          5. Medical history of gastrointestinal resection except appendectomy&#xD;
&#xD;
          6. Applicants testing positive for hepatitis B antigen, hepatitis C antibody, or HIV&#xD;
             antibody;&#xD;
&#xD;
          7. Clinically significant allergic diseases (excluding mild allergic rhinitis that does&#xD;
             not require medication)&#xD;
&#xD;
          8. Known history of hypersensitivity to drugs&#xD;
&#xD;
          9. Known history of developing complications such as epilepsy or other convulsive&#xD;
             diseases&#xD;
&#xD;
         10. Excessive consumption of caffeine and alcohol or heavy smoker&#xD;
&#xD;
         11. History of alcohol or drug abuse&#xD;
&#xD;
         12. Applicants who cannot take the standard meals provided by ASAN Medical Center(AMC)&#xD;
&#xD;
         13. Donation of whole or apheresis blood prior to the administration&#xD;
&#xD;
         14. Participation in other clinical study as subjects prior to the administration&#xD;
&#xD;
         15. Applicants who have taken prescription drugs prior to the administration or&#xD;
             OTC(over-the-counter) drugs prior to the administration and for which such medications&#xD;
             are judged by the principal investigator to have an influence on this study or on the&#xD;
             safety of the subject&#xD;
&#xD;
         16. Applicants who are highly likely to take other medication during the study&#xD;
&#xD;
         17. Applicants who took medication that induces or inhibits drug-metabolizing enzymes such&#xD;
             as barbiturates or consumed excessive amounts of alcohol less than 1 month prior to&#xD;
             the administration&#xD;
&#xD;
         18. Medical history of meningitis, encephalitis, or brain injury&#xD;
&#xD;
         19. Difficulty in cooperating with researchers in proceeding with the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

